Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S.

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

David Denton; Executive Vice President, Chief Financial Officer; Pfizer Inc Aamir Malik; Executive Vice President, Chief US Commercial Officer; Pfizer Inc Alexandre De Germay; Executive Vice President ...

Pfizer's CEO said tariff uncertainty is hindering ... In a first-quarter earnings call on Tuesday, chief executive Albert Bourla was asked what incentives he would want to see in tariff ...

Pfizer’s chief executive, Albert Bourla, told investors that the uncertainty surrounding President Donald Trump’s proposed tariffs on imported medicines is ...